×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:BGNE

BeiGene Stock Forecast, Price & News

$166.95
+5.10 (+3.15%)
(As of 07/1/2022 08:44 PM ET)
Add
Compare
Today's Range
$158.48
$169.04
50-Day Range
$121.11
$177.99
52-Week Range
$118.18
$426.56
Volume
225,000 shs
Average Volume
314,122 shs
Market Capitalization
$17.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$315.33

BeiGene MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
88.9% Upside
$315.33 Price Target
Short Interest
Bearish
1.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of BeiGene in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.18 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($15.54) to ($11.88) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.73 out of 5 stars

Medical Sector

814th out of 1,412 stocks

Pharmaceutical Preparations Industry

401st out of 673 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BeiGene logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

BGNE Stock News Headlines

BeiGene, Ltd. (NASDAQ:BGNE) COO Sells $145,803.60 in Stock
Why Shares of BeiGene Popped Today
Brokerages Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $315.33
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
8,200
Year Founded
2010

Company Calendar

Last Earnings
5/05/2022
Today
7/03/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$315.33
High Stock Price Forecast
$431.00
Low Stock Price Forecast
$177.00
Forecasted Upside/Downside
+88.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-1.41 billion
Net Margins
-218.25%
Pretax Margin
-219.11%

Debt

Sales & Book Value

Annual Sales
$1.18 billion
Book Value
$60.95 per share

Miscellaneous

Free Float
94,085,000
Market Cap
$17.24 billion
Optionable
Optionable
Beta
0.72

Social Links















BeiGene Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BeiGene stock.
View analyst ratings for BeiGene
or view top-rated stocks.

What is BeiGene's stock price forecast for 2022?

6 Wall Street analysts have issued 1-year price objectives for BeiGene's shares. Their BGNE stock forecasts range from $177.00 to $431.00. On average, they expect BeiGene's share price to reach $315.33 in the next year. This suggests a possible upside of 88.9% from the stock's current price.
View analysts' price targets for BeiGene
or view top-rated stocks among Wall Street analysts.

How has BeiGene's stock price performed in 2022?

BeiGene's stock was trading at $270.93 at the start of the year. Since then, BGNE stock has decreased by 38.4% and is now trading at $166.95.
View the best growth stocks for 2022 here
.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for BeiGene
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Thursday, May, 5th. The company reported ($4.24) EPS for the quarter, beating analysts' consensus estimates of ($4.52) by $0.28. The company had revenue of $306.60 million for the quarter, compared to analyst estimates of $300.41 million. BeiGene had a negative trailing twelve-month return on equity of 40.10% and a negative net margin of 218.25%. The company's revenue for the quarter was down 49.4% on a year-over-year basis.
View BeiGene's earnings history
.

Who are BeiGene's key executives?

BeiGene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, Exec. Chairman & CEO (Age 54, Pay $1.75M) (LinkedIn Profile)
  • Dr. Xiaobin Wu Ph.D., Pres, COO & GM of China (Age 60, Pay $1.64M)
  • Dr. Xiaodong Wang Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director (Age 59, Pay $250k)
  • Ms. Julia Wang, CFO & Principal Accounting Officer (Age 51, Pay $798.14k)
  • Mr. Wang Lai, Global Head of R&D (Age 45, Pay $1.13M)
  • Dr. Edna Huang M.D., Consultant (Age 49, Pay $768.08k)
  • Mr. Daniel Maller, VP of Fin. & Accounting
  • Ms. Mi Zhou, Sr. Director of Investor Relations
  • Mr. Kevin C. Mannix, Sr. VP of Investor Relations.
  • Mr. Scott Samuels, Sr. VP & Gen. Counsel

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $166.95.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $17.24 billion and generates $1.18 billion in revenue each year. The company earns $-1.41 billion in net income (profit) each year or ($20.090010) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 8,200 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for BeiGene is www.beigene.com. The company can be reached via phone at 861085148500 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.